Trial Pioneers Precision T Cell Therapy for Solid Tumors
Largest T Cell Clinical Trial in Solid Tumours Heralds New Era in Precision Immunotherapy
Tags: SingHealth Duke-NUS, Singapore, Healthcare & Lifesciences
The VANCE trial, the largest clinical study of T cell therapy for solid tumors, recruited 330 nasopharyngeal carcinoma (NPC) patients across Singapore, Malaysia, Thailand, Taiwan, and the U.S. Led by the National Cancer Centre Singapore, this international, phase III trial evaluated the efficacy of Epstein-Barr virus-specific cytotoxic T cell (EBV-CTL) therapy combined with chemotherapy. While overall survival improvement was not observed for the full cohort, a subset analysis in the U.S., Singapore, and Taiwan showed better outcomes for patients receiving the combined treatment. These results emphasize the potential for refining T cell therapies with biomarker identification to optimize treatment. T cell therapy is envisioned as a personalized approach for NPC, offering hope for improved precision in treating this Asian-prevalent cancer.
IP Type or Form Factor: Platform
TRL: 6 - prototype validated in intended environment
Industry or Tech Area: Biotechnology; Healthcare Provider
